<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018131</url>
  </required_header>
  <id_info>
    <org_study_id>0071</org_study_id>
    <nct_id>NCT04018131</nct_id>
  </id_info>
  <brief_title>The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy</brief_title>
  <official_title>The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy, a Study of Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ Serum Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extrinsic - atopic dermatitis is characterized by increased of IgE serum levels. Acute
      extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory
      mediator including Interleukin-4, Interleukin-12, and Interferon-Ɣ. Recent treatment of
      atopic dermatitis mainly focused on reducing the inflammation through topical and systemic
      regiments. However, no systemic medication could control the atopic dermatitis remission yet,
      and the current immunosuppressive agent used may cause many side effects if administered on a
      long term basis.

      In the future, treatment of atopic dermatitis were specifically targeted to inhibit the role
      of Th2. Cimetidine is H2 receptor antihistamine that has been widely used as gastrointestinal
      medication for a long time. Cimetidine could modulate the immune system by activating the Th1
      and lowering the Th2 activity, and lowering the IgE levels thus reducing the severity of
      atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to measure the efficacy of cimetidine for acute, extrinsic-atopic
      dermatitis treated with standard therapy using SCORAD as the clinical outcome. This study
      also measure Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ serum levels
      before and after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCORAD change</measure>
    <time_frame>0, 2, 4, 6, 8 weeks</time_frame>
    <description>Scoring Atopic Dermatitis (SCORAD) is a score to indicate the severity of atopic dermatitis.
The minimum score is 0, maximum score is 103. Mild 0 - 14 Moderate 15 - 39 Severe 40 - 103
The SCORAD before treatment was expected to be higher than after treatment. Outcome: change of SCORAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunoglobulin E change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Immunoglobulin E</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-4 change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Interleukin-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-12 change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Interleukin-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon Gamma change</measure>
    <time_frame>0, 8 weeks</time_frame>
    <description>Change of Interferon Gamma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Immunoglobulin E Concentration, Serum</condition>
  <arm_group>
    <arm_group_label>Cimetidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine</intervention_name>
    <description>Antihistamine 2 antagonist</description>
    <arm_group_label>Cimetidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopic dermatitis patients diagnosed with Hanifin Rajka criteria

          -  Acute extrinsic atopic dermatitis

          -  IgE levels above 200 IU/mL

          -  Minimum weight 15kg

        Exclusion Criteria:

          -  Consumption of corticosteroid and systemic immunosuppressant within the last 2 weeks

          -  Chronic lesion

          -  Consumption of drugs that reacts with cimetidine

          -  Disturbance in lab results including complete blood count, liver function, and renal
             function.

          -  Other conditions that might increase IgE levels
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Endi Novianto</last_name>
    <phone>+628161309063</phone>
    <email>drendinovianto@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Universitas Indonesia</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Endi Novianto, MD</last_name>
      <phone>+628161309063</phone>
      <email>drendinovianto@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Cimetidine</keyword>
  <keyword>Immunoglobulin E</keyword>
  <keyword>Interleukin-4</keyword>
  <keyword>Interleukin-12</keyword>
  <keyword>Interferon Gamma</keyword>
  <keyword>SCORAD</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

